# Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate

> **NCT00083005** · PHASE2 · COMPLETED · sponsor: **National Institutes of Health Clinical Center (CC)** · enrollment: 60 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** docetaxel
- **DRUG:** estramustine phosphate sodium
- **DRUG:** thalidomide

## Key facts

- **NCT ID:** NCT00083005
- **Lead sponsor:** National Institutes of Health Clinical Center (CC)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2012-03-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00083005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00083005, "Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00083005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*